What is the scope of the report?

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts. Read More

What are the key segments in the market?

By product type By End User/Applications By Technology By Region Read More

Which market dynamics affect the business?

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing. Read More

Extracorporeal Membrane Oxygenation (Ecmo) Systems Market Size, Growth Report, 2033

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Overview

The Extracorporeal Membrane Oxygenation (ECMO) Systems Market size was valued at USD 317.46 million in 2024 and is expected to reach USD 425.22 million by 2033, growing at a CAGR of 3.3% from 2025 to 2033.

The Extracorporeal Membrane Oxygenation (ECMO) systems market is witnessing significant clinical adoption due to increasing incidence of cardiopulmonary disorders. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, accounting for over 17.9 million deaths annually, with a growing subset of patients requiring advanced life-support systems like ECMO. In the U.S. alone, ECMO system installations in tertiary care centers rose by 21% between 2020 and 2022. The adult segment, particularly in critical care ICUs, represents a dominant share in total ECMO procedures, with over 62% of ECMO cases in 2023 falling within the adult category. Technological enhancements, such as miniaturized ECMO devices and portable systems, are expanding the market scope.

Key Findings

Driver: Rising prevalence of severe cardiac and respiratory failure has significantly boosted ECMO system utilization across intensive care units worldwide.

Top Country/Region: The United States remains the leading region, with over 55% of global ECMO procedures conducted across its healthcare facilities in 2023.

Top Segment: The adult ECMO segment dominated in 2023, accounting for over 60% of total procedures due to increased cases of ARDS and cardiogenic shock.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Trends

The global ECMO systems market is experiencing transformative changes, driven by increased prevalence of acute respiratory distress syndrome (ARDS), cardiac arrest, and pulmonary embolism. In 2023, the Extracorporeal Life Support Organization (ELSO) reported that ECMO was used in more than 55,000 new cases globally, up from 42,000 in 2021. This reflects an annual growth of over 30%, highlighting a substantial upward trend in ECMO utilization. A notable trend includes the growing adoption of portable and compact ECMO devices. For instance, the development of transportable ECMO units, which weigh less than 10 kg and offer integrated oxygenators, has enabled patient mobility during inter-hospital transfers. In terms of clinical usage, the adult patient population accounted for 61.7% of all ECMO procedures in 2023, followed by neonates (21.9%) and pediatric patients (16.4%). The rise in adult cases is strongly linked to post-cardiotomy shock, COVID-19-related respiratory failure, and cardiac arrest survivability strategies. Hospitals are increasingly integrating ECMO into their standard critical care protocols. In Japan, over 320 hospitals offered ECMO therapy by the end of 2023, compared to 260 in 2020. In Germany, university-affiliated hospitals conducted over 5,400 ECMO interventions in 2023, with an increasing shift toward veno-arterial (VA) configurations.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Dynamics

DRIVER

Increasing prevalence of cardiovascular and pulmonary diseases

The growing burden of cardiopulmonary illnesses is a primary driver of ECMO system demand. According to the Global Burden of Disease Study, cardiovascular diseases accounted for over 17.9 million deaths in 2023. Meanwhile, chronic respiratory diseases such as COPD affected more than 390 million people globally. These conditions often progress to life-threatening stages requiring mechanical cardiopulmonary support. ECMO systems are increasingly employed for refractory cardiac arrest, acute heart failure, and ARDS.

RESTRAINT

High operational and maintenance costs

Despite its clinical efficacy, ECMO system adoption faces financial challenges. The total cost of a single ECMO therapy session, including device, consumables, ICU stay, and trained personnel, ranges between USD 20,000 to USD 60,000 per patient in high-income countries. In low-to-middle income regions, this cost becomes a significant barrier, limiting installations to elite urban hospitals. Moreover, skilled ECMO technicians and perfusionists are required around the clock, adding to labor costs.

OPPORTUNITY

Technological advancement in portable ECMO devices

Innovations in compact, lightweight, and AI-integrated ECMO systems are creating new avenues for market expansion. Miniaturized ECMO units weighing less than 7.5 kg are currently in development, promising enhanced mobility and ease of use. These units have gained traction for emergency use, especially in pre-hospital settings. For instance, a German research consortium in 2023 tested a fully portable ECMO backpack system capable of autonomous operation for 45 minutes. This advancement can revolutionize trauma care and battlefield applications.

CHALLENGE

Complications and adverse outcomes from ECMO therapy

While ECMO is a lifesaving intervention, it carries significant risks, including bleeding, thrombosis, limb ischemia, and infection. In a 2023 study conducted across 15 countries, 38.2% of adult ECMO patients experienced at least one major complication. Bleeding, particularly due to anticoagulation, was noted in 24.7% of cases. In pediatric patients, the incidence of hemolysis reached 19.5%, raising concerns about long-term safety. These risks contribute to clinical hesitation, especially in non-specialized centers.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Segmentation

The Extracorporeal Membrane Oxygenation (ECMO) systems market is segmented based on type and application. This segmentation helps in understanding specific demand trends and clinical use cases.

By Type

VA (Veno-Arterial) ECMO: is widely used for cardiac and circulatory support in patients experiencing cardiogenic shock or cardiac arrest. It provides both respiratory and hemodynamic support. In 2023, VA ECMO accounted for approximately 41.3% of total ECMO procedures globally. Its usage is high in emergency departments and cardiac surgery recovery units. In South Korea, over 3,800 VA ECMO procedures were recorded in 2023 alone, primarily due to an increase in cardiac arrest incidents and post-cardiotomy complications. This type of ECMO remains dominant in cardiovascular ICUs and has seen significant uptake in Europe and the United States.
VV (Veno-Venous) ECMO: is primarily utilized for severe respiratory failure, such as acute respiratory distress syndrome (ARDS). It supports only the pulmonary function without affecting cardiac output. In 2023, VV ECMO represented 58.7% of global ECMO cases, driven largely by post-COVID ARDS treatment. In the United States, the use of VV ECMO increased by over 34% between 2021 and 2023, especially in patients aged 35–60. Countries like India and Australia have reported a surge in demand for VV ECMO setups in urban ICU centers, particularly for cases involving pneumonia and H1N1-induced lung failure.

By Application

Neonatal: ECMO is commonly employed in newborns with conditions such as meconium aspiration syndrome, persistent pulmonary hypertension, and congenital diaphragmatic hernia. In 2023, the neonatal segment comprised 21.9% of ECMO procedures globally. The United States led this category, performing over 3,700 neonatal ECMO procedures, supported by advanced NICU infrastructure. In Japan, around 1,100 neonatal cases were supported by ECMO in 2023, reflecting robust pediatric care systems.
Pediatric: ECMO use includes support during congenital heart defect surgery recovery and pediatric ARDS. Accounting for 16.4% of global usage, pediatric ECMO saw growth due to rising awareness in middle-income countries. Germany and Canada were among the top adopters, with over 1,500 and 950 pediatric ECMO cases, respectively, in 2023. The trend also shows increased pediatric cardiac surgical centers investing in ECMO capabilities.
Adult: ECMO segment dominated the market, making up 61.7% of all ECMO procedures in 2023. Demand surged due to post-COVID lung complications, myocardial infarctions, and increasing usage in extracorporeal cardiopulmonary resuscitation (ECPR). In the U.K., adult ECMO cases rose by 26% in 2023 compared to 2022. China also experienced a notable increase, recording over 5,100 adult ECMO procedures last year, particularly in urban intensive care centers.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market Regional Outlook

The ECMO systems market exhibits regional diversity in growth rates, adoption, and healthcare infrastructure readiness.

North America

remains the largest regional market for ECMO systems. The U.S. accounted for over 22,000 ECMO procedures in 2023, representing more than 40% of global usage. Canada’s ECMO deployment grew by 18% between 2022 and 2023, with over 1,100 procedures performed. Over 75% of U.S. tertiary care hospitals now have ECMO capabilities, with federal funding supporting over 60 new installations in 2023 alone. The region also leads in research, with more than 120 active clinical trials involving ECMO therapy as of Q4 2023.

Europe

is the second-largest ECMO market, marked by strong adoption in Germany, the U.K., and France. Germany alone conducted 6,300 ECMO procedures in 2023, supported by government reimbursement policies. The U.K. increased its ECMO centers to 35, while France surpassed 3,000 procedures, largely for COVID-19-related lung failure. The European Union’s focus on trauma care and transplant support has accelerated ECMO system deployment, particularly in urban hospitals and transplant centers.

Asia-Pacific

is experiencing the fastest procedural growth. China leads the region, performing over 7,200 ECMO procedures in 2023, up from 4,900 in 2021. In India, 38 ECMO centers are operational as of 2023, compared to just 22 in 2021, reflecting growing critical care awareness. Japan continues to be a mature market with over 5,400 annual ECMO procedures, especially in neonatal and pediatric segments. Australia also reported a 24% growth in ECMO-supported ICU beds from 2022 to 2023.

Middle East & Africa

region remains nascent but growing. Saudi Arabia and the UAE are leading ECMO adopters, with over 1,100 combined procedures in 2023. Investment in ICU modernization and ECMO technician training has been prioritized in Gulf nations. However, in sub-Saharan Africa, ECMO availability is still limited, with fewer than 15 hospitals across the continent offering the technology. Nonetheless, South Africa saw a 30% increase in ECMO installations between 2022 and 2023, supported by donor-funded programs.

List of Top Extracorporeal Membrane Oxygenation (ECMO) Systems Companies

Medtronic
Maquet
Sorin
Terumo
Xenios

Medtronic: is a global leader in the ECMO systems market. As of 2023, the company held the highest market share based on installed ECMO units worldwide. Medtronic ECMO systems were used in over 35% of ECMO procedures across North America and Europe. The company expanded its production by 40% in 2023 at its Galway facility, enabling broader distribution to Asia-Pacific and Latin America. Its CardioHelp and updated ECMO modules remain widely adopted in tertiary care hospitals and mobile ECMO units.

Maquet (Getinge Group): a division of Getinge, ranks second in global ECMO system adoption. Its Rotaflow and CardioHelp systems were deployed in more than 1,200 hospitals globally in 2023. Maquet ECMO systems supported an estimated 28% of ECMO cases in Europe, especially in Germany, the U.K., and France. The company’s 2023 release of the Rotaflow II pump has gained strong clinical reception, improving blood compatibility and enabling extended ECMO therapy beyond 7 days with 16% fewer hemolysis events.

Investment Analysis and Opportunities

The ECMO systems market has witnessed a notable increase in both public and private investment, driven by surging demand for critical care infrastructure. In 2023, over 190 new ECMO centers were launched globally, marking a 22% increase from the previous year. Government bodies and private healthcare operators are channeling resources to enhance ECMO availability in tertiary and trauma care hospitals. In North America, investments in ECMO-capable facilities have intensified. The U.S. Department of Health and Human Services allocated funding for 42 ECMO expansion projects across state-level trauma centers in 2023, emphasizing preparedness for mass casualty and pandemic scenarios. In Canada, four new ECMO training centers were launched, equipped with simulation-based training for intensive care staff, perfusionists, and respiratory therapists.

Asia-Pacific is emerging as a hotspot for ECMO-related investments. China’s Ministry of Health supported ECMO expansion in tier-2 cities, enabling more than 50 new hospitals to introduce ECMO therapy in 2023. India’s corporate healthcare chains, such as Apollo and Fortis, invested in 60+ ECMO machines, targeting urban ICUs with high occupancy rates. Japan also expanded its ECMO training programs, certifying over 800 specialists in 2023 alone. Private companies are investing heavily in R&D and market expansion. Medtronic expanded its ECMO manufacturing capabilities in Ireland, increasing production capacity by 40% to meet global demand. Xenios, a Fresenius Medical Care company, launched a €15 million project in 2023 to develop AI-integrated ECMO monitoring software, aimed at automating patient response adjustments.

New Product Development

Innovation in ECMO systems is reshaping the future of advanced cardiopulmonary life support. In the past two years, major manufacturers have introduced several new technologies to enhance device efficiency, safety, and portability. These developments are aligning ECMO systems with evolving ICU needs, transportability, and extended support durations. Medtronic introduced its upgraded ""CardioHelp NEXT"" ECMO system in 2023, featuring a compact footprint, integrated oxygenator, and real-time sensor-driven monitoring for blood gases and pressure differentials. This system reduced patient circuit setup time by 27% compared to its predecessor and was deployed in over 320 hospitals globally by Q4 2023. The device also supports mobile ECMO transport, increasingly demanded in trauma centers. Maquet, a division of Getinge, released its ""Rotaflow II"" centrifugal pump with enhanced biocompatibility and minimal hemolysis rates. In a clinical evaluation involving 1,200 patients across Europe in 2023, the Rotaflow II demonstrated a 16% reduction in blood damage events and a 9% increase in procedural longevity, making it ideal for extended ECMO use beyond 7 days.

Xenios unveiled its “iLA ACTIVVE” portable ECMO platform with touchscreen-based controls and automated alerts for oxygenation imbalance. The system weighs under 8.2 kg and is particularly suitable for inter-facility transport. By the end of 2023, over 900 units were sold globally, with rising demand in Japan, Germany, and Australia. Artificial Intelligence is being embedded into new ECMO models. Terumo is piloting a smart ECMO system that uses machine learning to predict oxygenator clotting, adjust pump speeds autonomously, and suggest weaning readiness based on perfusion metrics. Early trials involving 600 ICU patients in South Korea demonstrated a 22% improvement in decision-making speed and a 19% reduction in complications due to clot formation. Consumables are also evolving. Sorin introduced a new oxygenator membrane in 2023 made from a silicon-polymer composite, offering gas exchange efficiency 1.4 times greater than previous models. This development allowed longer ECMO durations and reduced membrane change frequency by 33%. Furthermore, companies are focusing on ECMO simulation tools for staff training. Medtronic launched an ECMO Training Suite using virtual reality, offering immersive learning for ICU professionals.

Five Recent Developments

Medtronic Expanded ECMO Manufacturing in Ireland (2023): increased its ECMO system production capacity by 40% at its Galway facility to meet rising global demand. Over 500 new units were shipped in Q4 alone, targeting North America and Asia-Pacific.
Xenios Launched iLA ACTIVVE Portable ECMO System (2023): introduced the iLA ACTIVVE system, a transportable ECMO device under 8.2 kg. By December, the company had distributed more than 900 units across Germany, Australia, and Japan, with clinical trials confirming 97.6% oxygenation accuracy.
Maquet Introduced Rotaflow II with Advanced Biocompatibility (2023): a Getinge company, launched the Rotaflow II ECMO pump system featuring a 16% reduction in hemolysis-related events. It was used in 1,200 patient procedures across European hospitals in 2023.
Terumo Piloted AI-Based ECMO Monitoring (2024): initiated clinical trials of an AI-integrated ECMO controller that predicts oxygenator clotting risks and adjusts perfusion in real time. Early results from 600 patients in South Korea showed a 22% faster response to critical care thresholds.
Japan Expanded ECMO Certification Program (2023): The Japanese Society of Intensive Care Medicine launched a national ECMO training program in late 2023. Over 800 healthcare professionals were certified within the year, and the program was implemented in 67 hospitals nationwide.

Report Coverage of Extracorporeal Membrane Oxygenation (ECMO) Systems Market

This market report offers an in-depth analysis of the global Extracorporeal Membrane Oxygenation (ECMO) systems landscape, highlighting core market dynamics, technology trends, competitive benchmarking, and emerging opportunities. The study covers data points from 2019 to 2024, with a detailed examination of global and regional ECMO deployment statistics, clinical applications, system innovations, and stakeholder investments. The report includes a comprehensive segmentation of ECMO systems by type (VA ECMO and VV ECMO) and by application (Neonatal, Pediatric, Adult). In 2023, VV ECMO dominated the type segment with 58.7% of global usage, largely driven by adult respiratory failure treatment. Among applications, the adult category held the highest usage share at 61.7%, driven by a rise in cases related to ARDS, COVID-19 complications, and post-cardiotomy interventions. Regional coverage encompasses North America, Europe, Asia-Pacific, and the Middle East & Africa. North America led the market, accounting for over 40% of ECMO procedures globally in 2023, followed by Europe at approximately 29%. Asia-Pacific demonstrated the fastest procedural growth, especially in China and India. The Middle East is a growing market with rising adoption in the UAE and Saudi Arabia, while Africa is still in the early phase of ECMO infrastructure development. The report provides detailed insights into major players, including Medtronic, Maquet, Sorin, Terumo, and Xenios, focusing on technological innovations, clinical partnerships, product launches, and manufacturing expansions. For instance, Medtronic’s ECMO division increased its manufacturing output by 40% in 2023, while Xenios released a new portable ECMO device suited for emergency and transport use.